A trial to test a new path for preventing Alzheimer’s
Last month, a wave of excitement swept through the world of Alzheimer’s research after Eli Lilly published results of a trial of their drug, donanemab. They found that the drug slowed cognitive decline in 47% of those who took the drug, vis-à-vis 29% who got a placebo. ‘Slowed’ here meant staving off the disease for … Read more